

April 8, 2025

Cuorips Inc.

**Announcement of Application for Approval of Manufacturing and  
Marketing of Human (Allogeneic) iPS Cell-derived Cardiomyocyte Patches**

Cuorips Corporation (hereafter, “the Company”) has been developing human (allogeneic) iPS cell-derived cardiomyocyte patches (hereafter, “cardiomyocyte patches”) for the treatment of severe heart failure due to ischemic cardiomyopathy, and today we are pleased to announce that we have submitted an application for approval of manufacturing and marketing of regenerative medicine products to the Ministry of Health, Labour and Welfare.

During the period between January 2020 and March 2023, eight cases of investigator-led clinical trials were conducted at four facilities including Osaka University Hospital.

The results of this clinical trial led to the recent application for approval.

The company will respond quickly to regulatory reviews and other processes in order to obtain approval as soon as possible, so that it can provide our as a new treatment option to patients.

The application itself do not have material impact on the company’s current fiscal consolidated P/L.

(please contact) [cuo\\_ir@cuorips.co.jp](mailto:cuo_ir@cuorips.co.jp)